肾癌异型性的免疫组化研究  

An immunohistochemical study on the heterogenicity of renal cell carcinoma

作　　者：陈至善[1] 熊显华[1] 

机构地区：[1]解放军第四五五医院

出　　处：《中华泌尿外科杂志》1996年第9期521-523,共3页Chinese Journal of Urology

摘　　要：为了探讨肾癌的异型性，对４２例肾癌应用抗ＣＤ_（１５）、抗上皮细胞膜抗原（抗ＥＭＡ）、抗神经元特异性烯醇化酶（抗ＮＳＥ）三种单抗，采用免疫组化ＡＢＣ法联合检测进行分类。肾癌Ａ型（＋、－、－）表达９例，分化好、异型性小、预后最好；肾癌Ｃ型（－、＋、＋）表达１３例，分化差、异型性大、预后最差；其余为Ｂ型，介于Ａ型和Ｃ型之间。结果提示肾癌ＣＤ_（１５）、ＥＭＡ、ＮＳＥ的表达与否，可表明癌细胞是否保留近曲小管上皮细胞的抗原性，可作为判断肾癌异型性的一个指标，与患者预后有关。Heterogenicity of renal cell carcinoma was detected in 42 cases by means of immunohistochemical method using anti CD15. EMA and NSE antibody. Nine cases were of type A renal cell carcinoma(+、-、 -),being well differentiated, with less heterogenicity and best expectancy. Thirteen were of type C renal cell carcinoma(-、+、+), being poorly differentiated, with much heterogenicity and worst expectancy. Type B was in between type A and type C,Expressions of CD15,EMA and NSE are probably the markers of heterogenicity in renal cell carcinoma and the heterogenicity is related to the prognosis of the patient.

关 键 词：肾肿瘤 癌 免疫化学 抗体 异型性 

分 类 号：R737.110.3[医药卫生—肿瘤] R730.3[医药卫生—临床医学]